These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 1687464)

  • 1. Effects of SDZ NVI-085, a putative subtype-selective alpha 1-agonist, on canine cataplexy, a disorder of rapid eye movement sleep.
    Renaud A; Nishino S; Dement WC; Guilleminault C; Mignot E
    Eur J Pharmacol; 1991 Nov; 205(1):11-6. PubMed ID: 1687464
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Further characterization of the alpha-1 receptor subtype involved in the control of cataplexy in canine narcolepsy.
    Nishino S; Fruhstorfer B; Arrigoni J; Guilleminault C; Dement WC; Mignot E
    J Pharmacol Exp Ther; 1993 Mar; 264(3):1079-84. PubMed ID: 8095546
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of central alpha-2 adrenergic compounds on canine narcolepsy, a disorder of rapid eye movement sleep.
    Nishino S; Haak L; Shepherd H; Guilleminault C; Sakai T; Dement WC; Mignot E
    J Pharmacol Exp Ther; 1990 Jun; 253(3):1145-52. PubMed ID: 1972749
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is SDZ NVI-085 an alpha 1-adrenoceptor subtype-selective agonist?
    Büscher R; Insel PA; Michel MC
    Life Sci; 1994; 54(14):999-1007. PubMed ID: 7908116
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of 5-HT1A receptor agonists and antagonists on canine cataplexy.
    Nishino S; Shelton J; Renaud A; Dement WC; Mignot E
    J Pharmacol Exp Ther; 1995 Mar; 272(3):1170-5. PubMed ID: 7891329
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Central alpha 1 adrenoceptor subtypes in narcolepsy-cataplexy: a disorder of REM sleep.
    Mignot E; Guilleminault C; Bowersox S; Frusthofer B; Nishino S; Maddaluno J; Ciaranello R; Dement WC
    Brain Res; 1989 Jun; 490(1):186-91. PubMed ID: 2569353
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The adrenoceptor agonist, SDZ NVI 085, discriminates between alpha 1A- and alpha 1B-adrenoceptor subtypes in vas deferens, kidney and aorta of the rat.
    Eltze M; Boer R
    Eur J Pharmacol; 1992 Dec; 224(2-3):125-36. PubMed ID: 1361446
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sulpiride, a D2/D3 blocker, reduces cataplexy but not REM sleep in canine narcolepsy.
    Okura M; Riehl J; Mignot E; Nishino S
    Neuropsychopharmacology; 2000 Nov; 23(5):528-38. PubMed ID: 11027918
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prostaglandin E2 and its methyl ester reduce cataplexy in canine narcolepsy.
    Nishino S; Mignot E; Fruhstorfer B; Dement WC; Hayaishi O
    Proc Natl Acad Sci U S A; 1989 Apr; 86(7):2483-7. PubMed ID: 2928344
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of central alpha-1 adrenoceptors in canine narcolepsy.
    Mignot E; Guilleminault C; Bowersox S; Rappaport A; Dement WC
    J Clin Invest; 1988 Sep; 82(3):885-94. PubMed ID: 2843574
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Trace Amine-Associated Receptor 1 Agonists as Narcolepsy Therapeutics.
    Black SW; Schwartz MD; Chen TM; Hoener MC; Kilduff TS
    Biol Psychiatry; 2017 Nov; 82(9):623-633. PubMed ID: 27919403
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activation of serotonin 5-HT1-receptors decreased gripping-induced immobility episodes in taiep rats.
    Ita ML; Cortés Mdel C; Valencia J; Eguibar JR
    Neurosci Lett; 2009 Jan; 449(2):147-50. PubMed ID: 18996171
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SDZ NVI 085, an alpha 1A-adrenoceptor agonist with 5-HT2A receptor antagonist properties.
    Lachnit WG; Ford AP; Clarke DE
    Eur J Pharmacol; 1996 Feb; 297(1-2):83-6. PubMed ID: 8851170
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evidence for a 5-HT1D receptor-mediated hypothermic effect of the alpha 1-adrenoceptor agonist, SDZ NVI-085, in guinea-pigs.
    Kalkman HO; Neumann V
    Eur J Pharmacol; 1995 Oct; 285(3):313-5. PubMed ID: 8575520
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nonpeptide orexin type-2 receptor agonist ameliorates narcolepsy-cataplexy symptoms in mouse models.
    Irukayama-Tomobe Y; Ogawa Y; Tominaga H; Ishikawa Y; Hosokawa N; Ambai S; Kawabe Y; Uchida S; Nakajima R; Saitoh T; Kanda T; Vogt K; Sakurai T; Nagase H; Yanagisawa M
    Proc Natl Acad Sci U S A; 2017 May; 114(22):5731-5736. PubMed ID: 28507129
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative effects of modafinil and amphetamine on daytime sleepiness and cataplexy of narcoleptic dogs.
    Shelton J; Nishino S; Vaught J; Dement WC; Mignot E
    Sleep; 1995 Dec; 18(10):817-26. PubMed ID: 8746387
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Hypersomnia. Narcolepsy-cataplexy (Gélineau syndrome)].
    Carlander B; Touchon J; Billiard M
    Presse Med; 1998 Nov; 27(34):1748-53. PubMed ID: 9835938
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thalidomide, a hypnotic with immune modulating properties, increases cataplexy in canine narcolepsy.
    Kanbayashi T; Nishino S; Tafti M; Hishikawa Y; Dement WC; Mignot E
    Neuroreport; 1996 Aug; 7(12):1881-6. PubMed ID: 8905685
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Electroencephalogram paroxysmal θ characterizes cataplexy in mice and children.
    Vassalli A; Dellepiane JM; Emmenegger Y; Jimenez S; Vandi S; Plazzi G; Franken P; Tafti M
    Brain; 2013 May; 136(Pt 5):1592-608. PubMed ID: 23616586
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Narcolepsy in the older adult: epidemiology, diagnosis and management.
    Chakravorty SS; Rye DB
    Drugs Aging; 2003; 20(5):361-76. PubMed ID: 12696996
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.